You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Related Headlines
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
BiBBInstruments signs first European distribution deal for EndoDrill GI with Palex Spain